Upfront Autologous Stem Cell Transplantation (ASCT) vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation with K Maintenance in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Phase 2 Non-Inferiority Cardamon Study
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Rakesh Popat(University College London Hospitals NHS Foundation Trust), William Wilson(Cancer Research UK), Jonathan Sive(University College London Hospitals NHS Foundation Trust), Elizabeth H. Phillips(University of Manchester), Tushar Dadaga(CRUK Lung Cancer Centre of Excellence), James D. Cavenagh(National Health Service), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), Michael A. Chapman(Toronto Metropolitan University), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Selina J Chavda(University College London), Ruth M. de Tute(St James's University Hospital), María Cuadrado(University College London), Reuben Benjamin(King's College London)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719